Bree Foster, PhD
Bree Foster is a science writer at Drug Discovery News with over 2 years of experience at Technology Networks, Drug Discovery News, and other scientific marketing agencies. She holds a PhD in comparative and functional genomics from the University of Liverpool and enjoys crafting compelling stories for science.
Articles by Bree Foster, PhD
| 4 min read
Without standardized, strain-level analysis, and clinically meaningful benchmarks, microbiome science will struggle to move from research into routine care.
| 4 min read
As the FDA shifts toward nonclinical methods, scientists weigh whether alternative technologies can match the predictive power of animal studies.
| 5 min read
While faster reviews could bring life-saving treatments to patients sooner, compressed timelines could also limit regulatory scrutiny and strain FDA resources.
| 4 min read
LYMPHIR delivers targeted therapy for a rare and incurable form of skin lymphoma while opening doors for broader immuno-oncology applications.
| 4 min read
A new drug may restore sexual function for men for months after just three days of dosing, offering hope for those who don’t respond to existing therapies.
| 4 min read
The FDA’s National Priority Voucher program aims to cut standard review times from potentially years to months, raising questions about safety, access, and public health impact.
| 3 min read
A physics-based urine test shows early promise in detecting bladder cancer recurrence without invasive procedures.
| 3 min read
Phase 2 trial shows that a topical drug rapidly reduces malodor, pain, and improves quality of life for patients with malignant fungating wounds.
| 8 min read
As nearly 90 percent of drugs fail in human trials, researchers are turning to patient-derived cells, engineered tissues, and AI to better predict human responses and reduce costly late-stage failures.
| 9 min read
Rather than replacing radiologists, AI is working alongside them to catch cancers earlier and improve screening efficiency.
| 5 min read
Early clinical data suggest that intratumoral delivery may halt tumor activity and support bone regeneration in metastatic breast cancer.
| 5 min read
Emerging optogenetic, gene, and cell therapies are moving beyond single-gene treatments, offering hope for a broader range of patients with retinitis pigmentosa.
